Published in
American Society of Hematology, Blood, p. blood-2018-01-825265
DOI: 10.1182/blood-2018-01-825265
Links
Tools
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Journal article published in 2018 by
Camille Guillerey 
,
Heidi Harjunpää,
Nadège Carrié,
Sahar Kassem ,
Tricia Teo,
Kim Miles,
Sophie Krumeich,
Marianne Weulersse,
Marine Cuisinier,
Kimberley Stannard,
Yuan Yu,
Simone A. Minnie ,
Geoffrey R. Hill ,
William C. Dougall ,
Hervé Avet-Loiseau
and other authors.
,
Heidi Harjunpää,
Nadège Carrié,
Sahar Kassem ,
Tricia Teo,
Kim Miles,
Sophie Krumeich,
Marianne Weulersse,
Marine Cuisinier,
Kimberley Stannard,
Yuan Yu,
Simone A. Minnie ,
Geoffrey R. Hill ,
William C. Dougall ,
Hervé Avet-Loiseau
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points TIGIT expression is upregulated on CD8+ T cells during MM progression and is associated with impaired effector functions. TIGIT deficiency or blockade protects mice against MM and improves effector functions of myeloma patient CD8+ T cells.